Randomized Controlled Trials Phase 3 Trials Efficacy Studies Drug Efficacy Patient Outcomes Dietary Interventions Vitamin D Studies Phase III Trials Fertility Treatments Data Analysis Phase II Trials Human Studies Weight Loss Studies Phase 3 Studies Drug Combinations Safety Testing Drug Testing Systematic Reviews Proof-of-Concept Trials Preclinical Studies Comparative Effectiveness Research Liver Fibrosis Treatments Placebo-Controlled Trials Pivotal Studies VITAL Trial Pharmaceutical Industry Pilot Studies Phase 1 Trials Pharmacology Long-term Outcomes Neurological Studies COSMOS Trial Phase I Trials FDA Approval DECAF Study Exercise Trials FDA Regulations Diagnostic Tests PROMISE Trial Regenerative Medicine Weight Loss Interventions Patient Studies Mylight Study Genomic Testing Cancer Research Validation Studies PREDIMED-Plus Trial Pediatrics Nutritional Studies Therapeutic Approaches Device Testing Targeted Therapies Approval Process Effectiveness Studies SELECT Trial Neuroimaging Genetic Research Substance Use Disorder Studies Vitamin D Trials Epidemiology Biomarkers Patient Care Therapeutic Innovations Trial Design Biomarker Discovery Vaccine Trials Metabolic Health Biopharmaceuticals Cardiovascular Disease Clinical Trials Addiction Research Randomized Trials Pediatric Health Medication Approval Patient Records Analysis Herbal Medicine Studies Observational Studies Diabetes Studies Urogynecology Patient Response Variability Diet Studies Neuroscience Studies Prospective Studies Phase 2 Trials Biomechanics Exercise Studies Therapeutics DECLARE-TIMI 58 Phase 1 Studies Psychiatric Disorders Phase II/III Studies Point-of-Care Testing Study Design Translational Medicine Psychedelic Research Patient Populations ASPREE Trial
Want to see what podcasts are saying about this topic? Search across 135K+ podcasts. Explore Radar
Researchers report that two pre-chemotherapy doses preserved mitochondrial trafficking through 5‑HT2A receptors, and the result has prompted a planned Phase II trial.
